Materias dentro de su búsqueda.
Mostrando 4,321 - 4,340 Resultados de 4,918 Para Buscar '"Pfizer"', tiempo de consulta: 0.24s Limitar resultados
  1. 4321
    “…Marshall, MD, GlaxoSmithKline (Consultant, Scientific Research Study Investigator)Merck (Consultant, Scientific Research Study Investigator)Pfizer (Consultant, Scientific Research Study Investigator)Sanofi Pasteur (Consultant, Grant/Research Support, Scientific Research Study Investigator, Honorarium for conference lecture)Seqirus (Consultant, Scientific Research Study Investigator)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1400. Physician Attitudes towards Combination Vaccine Use in Infants up to 24 months of age in the United States (US)
  2. 4322
    “…Grijalva, MD, MPH, AHRQ (Grant/Research Support)Campbell Alliance (Grant/Research Support)CDC (Grant/Research Support)FDA (Grant/Research Support)Merck (Consultant)NIH (Scientific Research Study Investigator)Pfizer (Consultant)Sanofi (Consultant)Sanofi (Grant/Research Support) Natasha B. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    67. SARS-CoV-2 Transmission: Preliminary Findings from a Household-based Study
  3. 4323
    “…Snydman, MD, Merck (Consultant)Merck (Advisor or Review Panel member)Pfizer (Consultant)Reviral, Anthrax Vaccine, Influenza Vaccine (Other Financial or Material Support, Data Safety Monitoring Board)Takeda/Shire (Advisor or Review Panel member)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1706. Association between Cytomegalovirus Infection/Disease and Morbidity and Mortality in Kidney Transplantation: A Systematic Literature Review of Observational Studies
  4. 4324
    “…Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor) Katherine Young, MS, Merck & Co., Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
  5. 4325
    “…They include: the mobilization of special government funding for vaccine purchase and distribution, timely contracting for a large amount of vaccines relative to Israel’s population, the use of simple, clear and easily implementable criteria for determining who had priority for receiving vaccines in the early phases of the distribution process, a creative technical response that addressed the demanding cold storage requirements of the Pfizer-BioNTech COVID-19 vaccine, and well-tailored outreach efforts to encourage Israelis to sign up for vaccinations and then show up to get vaccinated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Israel’s rapid rollout of vaccinations for COVID-19
  6. 4326
    “…(Funded by BioNTech and Pfizer; C4591001 ClinicalTrials.gov number, NCT04368728.)…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
  7. 4327
    “…We sought to characterize humoral immune responses, at high resolution, during immunization with the BNT162b2 (Pfizer-BioNTech) vaccine in individuals with or without prior history of natural SARS-CoV-2 infection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
  8. 4328
    “…Here we compare the effectiveness of two full-length Spike protein-encoding mRNA vaccines from Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) in the Mayo Clinic Health System over time from January to July 2021, during which either the Alpha or Delta variant was highly prevalent. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
  9. 4329
    “…INTERVENTIONS: BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine. MAIN OUTCOME MEASURES: Laboratory confirmed SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) and hospital admissions and deaths associated with SARS-CoV-2 infection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
  10. 4330
    “…We performed a prospective study to evaluate immune responses to COVID-19 vaccines (Moderna, Pfizer or Johnson & Johnson) in 62 liver transplant recipients, 79 patients with cirrhosis and 92 with chronic liver diseases without cirrhosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases
  11. 4331
    “…EXPOSURES: BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. MAIN OUTCOMES AND MEASURES: SARS-CoV-2 IgG antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD), and nucleocapsid protein (anti-NP). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
  12. 4332
    por Sattui, Sebastian Eduardo, Liew, Jean W, Kennedy, Kevin, Sirotich, Emily, Putman, Michael, Moni, Tarin T, Akpabio, Akpabio, Alpízar-Rodríguez, Deshiré, Berenbaum, Francis, Bulina, Inita, Conway, Richard, Singh, Aman Dev, Duff, Eimear, Durrant, Karen L, Gheita, Tamer A, Hill, Catherine L, Howard, Richard A, Hoyer, Bimba F, Hsieh, Evelyn, El Kibbi, Lina, Kilian, Adam, Kim, Alfred Hyoungju, Liew, David F L, Lo, Chieh, Miller, Bruce, Mingolla, Serena, Nudel, Michal, Palmerlee, Candace A, Singh, Jasvinder A, Singh, Namrata, Ugarte-Gil, Manuel Francisco, Wallace, John, Young, Kristen J, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Harrison, Carly, Larché, Maggie, Levine, Mitchell, Foster, Gary, Thabane, Lehana, Rider, Lisa G, Hausmann, Jonathan S, Simard, Julia F, Sparks, Jeffrey A
    Publicado 2021
    “…Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
  13. 4333
    “…METHODS: We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination with mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
  14. 4334
    “…INTRODUCTION: The Philippines pediatric national immunization program (NIP) included the 13-valent pneumococcal conjugate vaccine manufactured by Pfizer (PCV13-PFE) since 2015. Uptake has been slow in particular regions, with coverage only reaching all regions in 2019. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
  15. 4335
    “…From the 27th of December up to the 14th of March a total of 26,341 doses of Pfizer have been administered. 13,584 were first doses and 12,757 were second doses. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign
  16. 4336
    “…We assessed reactions reported during the 2 weeks after receipt of BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system
  17. 4337
    por Ebinger, Joseph E., Lan, Roy, Sun, Nancy, Wu, Min, Joung, Sandy, Botwin, Gregory J., Botting, Patrick, Al-Amili, Daniah, Aronow, Harriet, Beekley, James, Coleman, Bernice, Contreras, Sandra, Cozen, Wendy, Davis, Jennifer, Debbas, Philip, Diaz, Jacqueline, Driver, Matthew, Fert-Bober, Justyna, Gu, Quanquan, Heath, Mallory, Herrera, Ergueen, Hoang, Amy, Hussain, Shehnaz K., Huynh, Carissa, Kim, Linda, Kittleson, Michelle, Liu, Yunxian, Lloyd, John, Luong, Eric, Malladi, Bhavya, Merchant, Akil, Merin, Noah, Mujukian, Angela, Nguyen, Nathalie, Nguyen, Trevor-Trung, Pozdnyakova, Valeriya, Rashid, Mohamad, Raedschelders, Koen, Reckamp, Karen L., Rhoades, Kylie, Sternbach, Sarah, Vallejo, Rocío, White, Shane, Tompkins, Rose, Wong, Melissa, Arditi, Moshe, Figueiredo, Jane C., Van Eyk, Jennifer E., Miles, Peggy B., Chavira, Cynthia, Shane, Rita, Sobhani, Kimia, Melmed, Gil Y., McGovern, Dermot P.B., Braun, Jonathan G., Cheng, Susan, Minissian, Margo B.
    Publicado 2021
    “…In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Symptomology following mRNA vaccination against SARS-CoV-2
  18. 4338
    “…This study estimates the public health and economic impact of introducing either Pfizer’s 13-valent PCV (PCV13-PFE), GlaxoSmithKline’s 10-valent PCV (PCV10-GSK), or Serum Institute of India’s 10-valent PCV (PCV10-SII) into every pediatric SIP. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
  19. 4339
    “…Younger age, being female, prior SARS-CoV-2 infection, and receiving the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vs BNT162b2 (Pfizer-BioNTech) vaccine were associated with experiencing a reaction after the first vaccine dose. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
  20. 4340
    “…Vaccine type, 69.1% received Pfizer of which 80.5% had an undetectable SARS-CoV-2 antibody spike; Moderna 27.7%, of which 19.5% had an undetectable SARS-CoV-2 antibody spike.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
Herramientas de búsqueda: RSS